PATENT CLAIM ANALYSIS

Application Number: 15873520
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["435", "006000"]

Abstract:
This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.

Claim (Index 36):
The composition of  claim 31 , wherein the oligonucleotide is a labeled probe.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 86.0
- Lexical Diversity: 1.71186
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14943907', '13565044', '12098577', '13080262', '09675650']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6257855202415752
- 35 USC 102 Novelty (BERT): 0.5436047315156104
- Combined Prediction Score: 0.6175674413689787
- Mean Citation Score: 376.662426
- Max Citation Score: 399.81406
- Similarity Product: 247.8457319585252

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test